17 results about "Syk" patented technology

Provided herein are methods to treat neurodegenerative disease.

The invention relates to the field of antitumor drugs, in particular to a benzimidazole spleen tyrosine kinase inhibitor as well as a preparation method and application thereof. The inhibitor has a molecular structure as shown in a formula 1, in the formula 1, an R0 group is an R1 group containing an amide group, the R1 group is selected from at least one of the following groups, and an R3 group is selected from at least one of the following groups: H, F, Cl and Br; according to the benzimidazole inhibitor, the structure of the benzimidazole inhibitor can be optimized by introducing the R1 group of acylamino and the R2 group of multiple cyclic structures, so that efficient selective inhibition on spleen tyrosine kinase (Syk) is realized.

Provided are methods for determining if an individual is likely to experience immune-related adverse events (irAEs) if treated for melanoma with a combination of immune checkpoint inhibitors that are an anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) antibody and an anti-programmed death-ligand 1 (PD-1) antibody. The methods include determining differential gene signatures as between individuals who had melanoma and were treated with a combination of a CTLA-4 antibody and an PD-1 antibody but did not experience severe irAEs after the treatment, with the gene signature for an individual who has melanoma but was not treated with an immune checkpoint inhibitor.

The present invention relates to pyrazolyl-pyrimidine derivatives, methods for their preparation, pharmaceutical compositions comprising them, and their use as therapeutic agents. These compounds are kinase inhibitors, particularly inhibitors of spleen tyrosine kinase (SYK), and can be used to treat cancer, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders, and cardiovascular diseases.

Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1 / H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.

The invention provides an ITK-SYK fusion gene detection kit and detection method based on ultra-high depth sequencing, the ITK-SYK fusion gene detection kit comprises a plurality of primers, the detection method uses obtained cf-RNA as a template to amplify a target sequence and build a library, the obtained library is sequenced, offline data is analyzed, and the detection result of the ITK-SYK fusion gene detection kit based on ultra-high depth sequencing is obtained. And calculating the relative proportion of the ITK-SYK fusion gene. According to the detection method, the limit of digital PCR is broken through, the designed amplified fragment is shorter, the detection sensitivity is further improved, an SE50-SE75 short read length mode is used during sequencing, ultrahigh sequencing depth is achieved under the condition of extremely small data volume, 10 <-6 > low-frequency fusion mutation can be detected, the time required by the overall experimental process is as short as 1 day, and the report period is greatly shortened. The method is high in specificity, high in sensitivity, simple, convenient and rapid to operate and rigorous and reliable in result, provides a reliable method for related research of ITK-SYK gene fusion diseases, and is a convenient and non-invasive detection technology.

Methods for treating leukemia are disclosed based on detecting specific cell states and transcriptional programs within leukemic cells. This disclosure presents a novel therapeutic method for treating acute lymphoblastic leukemia (ALL), including BCR-ABL positive and BCR-ABL1-like ALL subtypes. The method involves detecting specific cell states and transcriptional programs in patient samples and administering targeted therapies based on these characteristics. For a pre-B cell-like state or pre-BCR signaling program, a combination of tyrosine kinase inhibitor (TKI) and SYK inhibitor is used. Conversely, a progenitor-like state or stress-autophagy program is treated with a TKI and a p38 MAPK inhibitor. This approach aims to improve treatment efficacy by tailoring therapy to the leukemia's unique molecular and cellular features, particularly in relapsed cases or when minimal residual disease is present.

The invention relates to application of a compound 101-mer in preparation of an influenza vaccine adjuvant and an influenza vaccine, and belongs to the technical field of biology. The compound 101-mer is used as an influenza vaccine adjuvant for preparing an influenza vaccine, the immune protection effect of the influenza vaccine can be improved, the specific total IgG antibody titer of an influenza antigen and IgG1, IgG2a, IgG2b and IgG3 subtype antibody levels are improved, complete protection is provided after challenge, tissue damage is relieved, and the antiviral activity is remarkably superior to that of compounds 18-mer, 19-mer, 27-mer and LPS; as an adjuvant, the compound 101-mer does not have observable toxicity, can still be well tolerated under a high dosage, and has relatively high safety, and the safety of the compound 101-mer is remarkably superior to that of LPS (Lipopolysaccharide); the action mechanism is clear, and the compound can be used as a Dectin-2 agonist to activate a host immune system through a Syk / NF-kappa B signal channel.

Provided are a salt form and a crystal form of a pyrazole substituted imidazo[1,2-a]quinoxaline derivative, and a preparation method therefor. Specifically disclosed are a salt form and a crystal form of a compound of formula (I), and a preparation method therefor and the use thereof in the preparation of drugs related to dual inhibitors of spleen tyrosine kinase (Syk) and vascular endothelial growth factor 2 (VEGFR2).

Provided herein, inter alia, are methods of treating chemical or radiation-induced lung injury by administering to a subject Fosatinib, an active ingredient thereof, or a pharmaceutically acceptable salt thereof.

The present invention provides compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk.

The present invention relates to a SYK gene SNP primer and application related to the isovaleric acid content in musk deer, and belongs to the field of biotechnology. The present invention provides a SYK gene SNP primer related to the isovaleric acid content trait in musk deer, the deoxyribonucleotide sequence of the SNP primer is as shown in SEQ ID NO: 1 and SEQ ID NO: 2, the SNP is located at the 25879500th base of chromosome 7 of the musk deer reference genome, the base mutation is A or G, and the genotype is GG, AG. The detection method disclosed in the present invention is simple and easy to operate, can be carried out in the laboratory, and can also be applied to genomic breeding technology. Its beneficial effect is that it can efficiently and quickly identify the relative content trait of isovaleric acid in musk deer, providing a scientific basis for the early breeding of high-quality musk deer.

Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1 / H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.

This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a compound containing an imidazo[1,2-a]pyrazine fragment, its preparation method, and its applications. The compound containing the imidazo[1,2-a]pyrazine fragment of this invention exhibits significant inhibitory activity against SYK, and also significantly inhibits the proliferation of tumor cells, particularly breast cancer cells, ovarian cancer cells, and liver cancer cells. Furthermore, it can induce apoptosis in ovarian cancer cells, thus providing a novel option for SYK inhibitors used in the treatment of solid tumors.

The invention relates to the use of AT7867, MC1568, ACY-1215, AZD-4547, NPK76- II-72-1, tivozanib, SAR-245409, HG-9-91-01, BIX-01294, UNC-669, WZ-7043, dacomitinib, CC-401, UNC-0638, epigallocatechin gallate (-), SB-239063, GDC-0879, KIN001-260, quizartinib, CGK-733, UNC-1215, XMD11-85H, garcinol, PF-573228, veliparib, VE-821, NVP-TAE684, GSK-J2, masitinib, KU-55933, KIN001-127, KIN001- 270, vandetanib, CG-930, GNF-2, decitabine, SGI-1776, amuvatinib, BS-181, CTB, MGCD-265, olaparib, ZM-447439, AGK-2, bosutinib, JNJ-38877605, RG-108, SYK- inhibitor, AZ-20, and OSI-930 drugs, which aim to suppress immune system escape mechanisms in cancer treatment and reduce the proliferation and survival abilities of cancer cells by interacting with proteins involved in immune escape processes and / or neighbouring proteins of these proteins, in T-cell-based immunotherapies.

The invention provides a salt form, a crystal form and a preparation method of a pyrazole-substituted imidazo [1, 2-a] quinoxaline derivative, and particularly discloses a salt form, a crystal form and a preparation method of a compound shown in a formula (I), and application of the compound in preparation of spleen tyrosine kinase (Syk) and vascular endothelial growth factor 2 (VEGFR2) dual-inhibitor related drugs.

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.